| Literature DB >> 32386566 |
Eija Pirinen1, Mari Auranen2, Nahid A Khan3, Virginia Brilhante3, Niina Urho4, Alberto Pessia5, Antti Hakkarainen6, Juho Kuula7, Ulla Heinonen4, Mark S Schmidt8, Kimmo Haimilahti9, Päivi Piirilä10, Nina Lundbom7, Marja-Riitta Taskinen9, Charles Brenner8, Vidya Velagapudi5, Kirsi H Pietiläinen11, Anu Suomalainen12.
Abstract
NAD+ is a redox-active metabolite, the depletion of which has been proposed to promote aging and degenerative diseases in rodents. However, whether NAD+ depletion occurs in patients with degenerative disorders and whether NAD+ repletion improves their symptoms has remained open. Here, we report systemic NAD+ deficiency in adult-onset mitochondrial myopathy patients. We administered an increasing dose of NAD+-booster niacin, a vitamin B3 form (to 750-1,000 mg/day; clinicaltrials.govNCT03973203) for patients and their matched controls for 10 or 4 months, respectively. Blood NAD+ increased in all subjects, up to 8-fold, and muscle NAD+ of patients reached the level of their controls. Some patients showed anemia tendency, while muscle strength and mitochondrial biogenesis increased in all subjects. In patients, muscle metabolome shifted toward controls and liver fat decreased even 50%. Our evidence indicates that blood analysis is useful in identifying NAD+ deficiency and points niacin to be an efficient NAD+ booster for treating mitochondrial myopathy.Entities:
Keywords: NAD(+); NAD(+) repletion; mitochondria; mitochondrial disease; mitochondrial myopathy; mtDNA deletions; niacin; respiratory chain deficiency; treatment; vitamin B3
Year: 2020 PMID: 32386566 DOI: 10.1016/j.cmet.2020.04.008
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287